<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; chris</title>
	<atom:link href="http://www.tapanray.in/tag/chris/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>A Potential Game Changer For Pharma R&amp;D</title>
		<link>http://www.tapanray.in/a-potential-game-changer-for-pharma-rd/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-potential-game-changer-for-pharma-rd</link>
		<comments>http://www.tapanray.in/a-potential-game-changer-for-pharma-rd/#comments</comments>
		<pubDate>Mon, 10 Feb 2014 00:00:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Abdul]]></category>
		<category><![CDATA[Alzheimer's]]></category>
		<category><![CDATA[AMP]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[Changer]]></category>
		<category><![CDATA[chris]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[Collaborative]]></category>
		<category><![CDATA[CSIR]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kalam]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[OHE]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[viehbacher]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4974</guid>
		<description><![CDATA[The ghost of ‘Patent Cliff’ has been haunting the ‘Big Pharma’ since quite some time. This situation has been further aggravated by cost containment pressures of various Governments both in the developed and the emerging markets together with contentious issues &#8230; <a href="http://www.tapanray.in/a-potential-game-changer-for-pharma-rd/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-potential-game-changer-for-pharma-rd/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Seeing ghosts where there aren&#8217;t any</title>
		<link>http://www.tapanray.in/seeing-ghosts-where-there-arent-any/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=seeing-ghosts-where-there-arent-any</link>
		<comments>http://www.tapanray.in/seeing-ghosts-where-there-arent-any/#comments</comments>
		<pubDate>Mon, 10 Oct 2011 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[any]]></category>
		<category><![CDATA[aren't]]></category>
		<category><![CDATA[attractive]]></category>
		<category><![CDATA[chris]]></category>
		<category><![CDATA[ghosts]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Seeing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[there]]></category>
		<category><![CDATA[viebachar]]></category>
		<category><![CDATA[where]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=190</guid>
		<description><![CDATA[Seeing ghosts almost everywhere in the Indian pharmaceutical industry, especially where there aren&#8217;t any, has indeed become quite common nowadays, across the spectrum of stakeholders. The ‘ghosts’ could well reside in ‘100% Foreign Direct Investments (FDI) through automatic route in &#8230; <a href="http://www.tapanray.in/seeing-ghosts-where-there-arent-any/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/seeing-ghosts-where-there-arent-any/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
